# Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

> **NCT00640978** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** RAD001
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00640978
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Significant Adverse Effects - Futility
- **Last updated:** 2025-05-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00640978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00640978, "Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00640978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*